To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

DIABETES DRUGS

TODAY'S HEADLINES

New diabetes drug enters competitive market

FDA just approved a new medication to treat type 2 diabetes. The drug enters a lucrative but competitive diabetes treatment market, which includes top-sellers such as Lantus, Januvia and Humalog. Read more

First 4-strain flu vaccine available

FDA recently approved the first 4-strain, cell culture-derived, inactivated seasonal flu vaccine available in the US. Flucelvax Quadrivalent influenza vaccine helps protect against the 2 influenza A viruses as well as 2 influenza B viruses. Read more

CONTINUING PHARMACY EDUCATION

Keep your patients moving: An overview of treatment options for constipation

This month's CE activity, "Keep your patient moving: An overview of treatment options for constipation," is open for pharmacists and pharmacy technicians.
The goal of this program is to assist pharmacists and pharmacy technicians in their understanding of the role of linaclotide, lubiprostone, methylnaltrexone, and naloxegol in the treatment of constipation after conventional nonpharmacologic interventions and conventional laxatives such as bulking agents, osmotic laxatives, and stimulant laxatives have failed.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

New treatment for kidney cancer gets OK

FDA recently approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma. Read more

June 3, 2016

Related Articles

Major diabetes drug cuts heart attack risk

Visterra gets $29 million to develop novel flu drug

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply.
Please use the links provided if you have questions or concerns regarding this email or your subscription.

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters
Contact Us